Q3 2024 Cytosorbents Corp Earnings Call Transcript
Key Points
- CytoSorbents Corp (CTSO) reported Q3 2024 product sales of $8.6 million, exceeding their guidance range and reflecting an 11% year-over-year growth.
- The company achieved a product gross margin of 61% for the quarter, which was above their guided range.
- Operating expenses decreased by 25% year-over-year, leading to a 40% reduction in operating loss and a lower cash burn of $2.7 million for the quarter.
- CytoSorbents Corp (CTSO) has submitted its De Novo medical device marketing application for Drugsorb A TR to the FDA and Health Canada, with regulatory decisions expected in 2025.
- The company has received positive feedback on its newly launched purified hemoperfusion pump, which is expected to drive increased demand for its CytoSorb cartridges.
- Product gross margins decreased from 72% in the prior year's quarter due to a planned production slowdown and a short-term manufacturing issue.
- Grant revenue decreased to $800,000 from $1.1 million in the prior year due to the conclusion of several grants.
- The primary endpoint of the Star T trial was not met in the allcomers surgery population, although it was met in the isolated CABG population.
- The company has $12.2 million in cash, including $6.5 million of restricted cash, indicating limited liquidity.
- CytoSorbents Corp (CTSO) faces uncertainty regarding the timeline for FDA approval, with expectations set for sometime in 2025.
Thank you for standing by. My name is Catherine and I will be your conference operator today. At this time. I would like to welcome everyone to the site of Cytosorbents Corporation third quarter, 2024 earnings call. (Operator Instructions)
Thank you. I would now like to turn the call over to Investor Relations consultant, Adana Alexander. Please go ahead.
Thank you, Katherine and good afternoon, everyone, welcome to side the SOS third quarter, 2024 financial and operating results conference call. Joining me today from the company for the prepared remarks are of Phillip Chan, Chief Executive Officer; and Pete Mariani, Chief Financial Officer for the Q&A portion of the call. Dr. Chan and Mr, Mariani will be joined by Phil Capone, President and Chief Operating Officer, Doctor Micas da Gis, Chief Medical Officer, Dr Christian Steiner, Executive Vice President of sales and marketing and managing director of Stos Europe and Christian Kramer, Senior Vice President of Business Development.
Before I turn the call over to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
